A patient arrives having read three forums and a podcast transcript. You have about ninety seconds to work out whether what they are asking for is reasonable.
Most peptide information online is written to sell a vial. It is optimised for confidence, not accuracy, and it rarely tells you where the evidence stops.
What a clinician needs is narrower and duller: what the compound does, what has actually been studied, at what doses, in whom, and what would make you say no.
74 protocol sheets covering mechanism, researched indications, dosing ranges, administration routes, contraindications, drug interactions and citations. Built to be read between patients rather than studied.
Compounds are tiered by evidence quality, and the tiering is deliberately conservative. Where human data is thin, the sheet says so instead of implying more.
Whether a compound sits inside 503A or 503B compounding, and what the July 2026 advisory vote changed, which is considerably less than the coverage suggested.
Full access to the protocol reference, compliance guides and regulatory briefings.
Get Professional access → Or see everything that is included